Valo Health
Valo is a technology company built to transform drug discovery and development using large-scale data and AI-powered computation. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease.www.valohealth.com
4
MENTIONS
2
EPISODES
2
PODCASTS
Search complete. 4 mentions across 2 episodes found for "Valo Health".
Sep 18, 2026
Sharon CoxHOST
We talk about the career decision that changed everything, why she left one of the biggest names in pharma for an emerging AI-enabled biotech, the future of drug discovery, and what leadership really means when you're responsible for inspiring the next generation of scientists.
Sharon CoxHOST
So please welcome Chief Scientific Officer at Valo Health, Karen Conde-Knappe.
Karin Conde-KnapeGUEST
Karen, hi, good afternoon.
Karin Conde-KnapeGUEST
Hi, Sharon.
Jim CornallHOST
Well, hopefully we will have Karsten on again when they have some more good news.
Jim CornallHOST
Next, we're going to talk about AI and drug discovery with Valo Health Chief Scientific Officer, Karine Konde-Kanapa.
Jim CornallHOST
Valo Health works on drug discovery and development through its AI-enabled human causal biology and closed-loop chemistry platforms, and it has its own pipeline.
Jim CornallHOST
Hi, Corinne.
Jim CornallHOST
Great to have you on the podcast today.
Karin Conde-KnapeGUEST
Yeah, so I have spent more than 20 years in the pharma industry, in big pharma and multiple pharmas, always in the early phases of target ID towards early clinical development.
Karin Conde-KnapeGUEST
And I have always been very curious as to how are we enabling better patient understanding if we are really serious about bringing differentiated treatments.
Karin Conde-KnapeGUEST
And during my tenure at Novo Nordisk, I was lucky to come across Valo Health as a company that was precisely intending and as a mission having this connection of understanding of the patient and then delivering better treatments.